Apis Capital Advisors LLC Acquires Shares of 79,481 Harrow, Inc. (NASDAQ:HROW)

Apis Capital Advisors LLC bought a new position in shares of Harrow, Inc. (NASDAQ:HROW) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 79,481 shares of the company’s stock, valued at approximately $1,660,000. Harrow makes up about 1.2% of Apis Capital Advisors LLC’s investment portfolio, making the stock its 26th largest holding. Apis Capital Advisors LLC owned 0.22% of Harrow at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the business. Price T Rowe Associates Inc. MD lifted its holdings in Harrow by 6.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 16,672 shares of the company’s stock worth $221,000 after buying an additional 1,033 shares during the last quarter. nVerses Capital LLC acquired a new position in Harrow in the second quarter valued at approximately $33,000. BNP Paribas Financial Markets increased its stake in Harrow by 12.7% in the first quarter. BNP Paribas Financial Markets now owns 16,941 shares of the company’s stock valued at $224,000 after purchasing an additional 1,912 shares during the last quarter. Allspring Global Investments Holdings LLC increased its stake in Harrow by 2,730.7% in the second quarter. Allspring Global Investments Holdings LLC now owns 2,123 shares of the company’s stock valued at $44,000 after purchasing an additional 2,048 shares during the last quarter. Finally, Equitable Trust Co. raised its holdings in Harrow by 2.9% during the first quarter. Equitable Trust Co. now owns 83,500 shares of the company’s stock worth $1,105,000 after purchasing an additional 2,345 shares in the last quarter. Hedge funds and other institutional investors own 72.76% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on HROW. B. Riley reissued a “buy” rating and issued a $50.00 target price on shares of Harrow in a research report on Thursday, August 29th. Craig Hallum increased their price target on shares of Harrow from $30.00 to $45.00 and gave the stock a “buy” rating in a research note on Friday, August 9th. Finally, Lake Street Capital upped their target price on shares of Harrow from $20.00 to $25.00 and gave the company a “buy” rating in a report on Monday, June 3rd.

Harrow Trading Down 3.1 %

NASDAQ:HROW opened at $45.02 on Monday. Harrow, Inc. has a 12-month low of $7.60 and a 12-month high of $47.55. The company has a current ratio of 2.60, a quick ratio of 2.43 and a debt-to-equity ratio of 3.18. The stock’s 50 day simple moving average is $34.70 and its 200-day simple moving average is $22.02. The firm has a market cap of $1.60 billion, a P/E ratio of -49.47 and a beta of 0.75.

Harrow (NASDAQ:HROW) last announced its quarterly earnings data on Wednesday, August 7th. The company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.12. The company had revenue of $48.94 million for the quarter, compared to analyst estimates of $42.78 million. Harrow had a negative return on equity of 40.59% and a negative net margin of 21.78%. Equities analysts anticipate that Harrow, Inc. will post -0.38 EPS for the current year.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.